The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review


Synonyms: Camptosar, irinotecan, Irinotecanum, Irinotecan Hcl, CHEMBL481, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Biotecan


Associations of Biotecan with other chemical compounds


Gene context of Biotecan

  • In combination with UGT1A1*28 genotyping, CYP3A4 phenotype determination should be explored further as a strategy for the individualization of irinotecan treatment [8].


  1. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Minami, H., Sai, K., Saeki, M., Saito, Y., Ozawa, S., Suzuki, K., Kaniwa, N., Sawada, J., Hamaguchi, T., Yamamoto, N., Shirao, K., Yamada, Y., Ohmatsu, H., Kubota, K., Yoshida, T., Ohtsu, A., Saijo, N. Pharmacogenet. Genomics (2007) [Pubmed]
  2. Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Hoskins, J.M., Marcuello, E., Altes, A., Marsh, S., Maxwell, T., Van Booven, D.J., Paré, L., Culverhouse, R., McLeod, H.L., Baiget, M. Clin. Cancer Res. (2008) [Pubmed]
  3. Clinical determinants of response to irinotecan-based therapy derived from cell line models. Allen, W.L., Coyle, V.M., Jithesh, P.V., Proutski, I., Stevenson, L., Fenning, C., Longley, D.B., Wilson, R.H., Gordon, M., Lenz, H.J., Johnston, P.G. Clin. Cancer Res. (2008) [Pubmed]
  4. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Desjardins, A., Reardon, D.A., Herndon, J.E., Marcello, J., Quinn, J.A., Rich, J.N., Sathornsumetee, S., Gururangan, S., Sampson, J., Bailey, L., Bigner, D.D., Friedman, A.H., Friedman, H.S., Vredenburgh, J.J. Clin. Cancer Res. (2008) [Pubmed]
  5. Experience with irinotecan for the treatment of malignant glioma. Vredenburgh, J.J., Desjardins, A., Reardon, D.A., Friedman, H.S. Neuro-oncology (2009) [Pubmed]
  6. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Loghin, M.E., Prados, M.D., Wen, P., Junck, L., Lieberman, F., Fine, H., Fink, K.L., Metha, M., Kuhn, J., Lamborn, K., Chang, S.M., Cloughesy, T., DeAngelis, L.M., Robins, I.H., Aldape, K.D., Yung, W.K. Clin. Cancer Res. (2007) [Pubmed]
  7. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Javle, M.M., Cao, S., Durrani, F.A., Pendyala, L., Lawrence, D.D., Smith, P.F., Creaven, P.J., Noel, D.C., Iyer, R.V., Rustum, Y.M. Clin. Cancer Res. (2007) [Pubmed]
  8. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. van der Bol, J.M., Mathijssen, R.H., Creemers, G.J., Planting, A.S., Loos, W.J., Wiemer, E.A., Friberg, L.E., Verweij, J., Sparreboom, A., de Jong, F.A. Clin. Cancer Res. (2010) [Pubmed]
WikiGenes - Universities